This inventor holds 5 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: Gilead Sciences, Inc., Janssen Sciences Ireland Uc. Active years: 2020-2026.
Company Filing History:
5 out of 946 
1 out of 111 
Years Active: 2020-2026
Title: Scott McCallister: Innovator in HIV Treatment
Introduction
Scott McCallister is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of medicine, particularly in the treatment of HIV. His innovative approach has led to the development of a patent that addresses the needs of individuals infected with this virus.
Latest Patents
Scott McCallister holds a patent for "Compositions and methods of treating HIV." This patent focuses on methods of treating subjects infected with HIV using a once-daily regimen. The treatment involves single unit dosage forms that include darunavir, cobicistat, emtricitabine, and a tenofovir prodrug or its salt. This innovative method aims to improve the quality of life for those living with HIV.
Career Highlights
Throughout his career, Scott has worked with prominent companies in the pharmaceutical industry. He has been associated with Janssen Sciences Ireland UC and Gilead Sciences, Inc. These experiences have allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Scott has worked alongside talented individuals such as Katia Boven and Goedele De Smedt. Their collaborative efforts have played a crucial role in advancing research and development in HIV treatment.
Conclusion
Scott McCallister's contributions to HIV treatment through his innovative patent demonstrate his commitment to improving healthcare. His work continues to inspire advancements in medical science and offers hope to many individuals affected by HIV.